John Cooper

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 218 citations · Full text

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Matthias von Herrath, Stephen C. Bain, Bruce W. Bode et al. · The Lancet Diabetes & Endocrinology · 2021 · 163 citations · Full text

Inflammation, β-Cell Function, Diabetes Management +7

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

Priscilla Hollander, John Cooper, Jesper Flethøj Bregnhøj et al. · Clinical Therapeutics · 2008 · 162 citations

Obesity, Diabetes Management, Insulin Glargine +8